REG - BSF Enterprise PLC - MoU with Sustainable Fashion Company

BSF EnterpriseAnnouncement

29/02/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240229:nRSc8731Ea&default-theme=true

RNS Number : 8731E  BSF Enterprise PLC  29 February 2024

29 February 2024

BSF Enterprise PLC

("BSF" or the "Company")

 

MoU with Sustainable Fashion Company Amelie Pichard

 

3DBT and Amelie Pichard to produce World's First Fashion Accessory using
Lab-Grown Leather

 

BSF (LSE: BSFA), (OTCQB: BSFAF), the Main Market listed biotech company and
owner of pioneering UK-based tissue engineering company 3D Bio-Tissues (3DBT)
and corneal tissue replacement company Kerato, announces that 3DBT has signed
an MoU with Maison Amelie Pichard (https://ameliepichard.com/en/) , a fashion
company that designs and makes products using environmentally friendly
materials.

 

The collaboration will explore future commercial opportunities, working
together to develop, manufacture, and ultimately sell fashion accessories that
incorporate lab-grown leather. This is a milestone event, marking the first
time real lab-grown leather has been ethically produced for the fashion
industry using the same structures as traditional leather, without the need
for plant-based scaffolds, making it suitable for traditional craft purposes.

 

Amelie Pichard's business model is based around sustainability, making batches
of bags and shoes on demand only when prior batches have sold out to minimise
waste and repairing and reselling products to maximise their lifetime. Using a
plethora of materials, such as eel Leather, upcycled denim, natural cork,
cactus, pinatex (pineapple leaves), and, with 3DBT, lab-grown leather, the
Amelie Pichard seeks to work with the most future-proofed and environmentally
friendly options for materials.

 

The collaboration is seeking to reduce reliance on leather in its products
rather than eliminate the use, therefore incorporating elements of lab-grown
leather within the production process. BSF will work to develop many different
products that can be used both in production and in repair for resale,
enabling more rapid improvement in the development process.

 

As reported in its recent strategic update, BSF expects to establish its
lab-grown leather offering as a separate subsidiary company, Lab-Grown Leather
Limited, in H2 2024. This will enable the development and sales of its animal
skin products to be scaled up to meet the substantial market opportunity. The
leather goods market was valued at $253 billion in 2023 and is forecast to
grow to $405 billion by 2030.

 

The Company is also in the process of building a leather tanning capability
within its laboratory at Newcastle. A further announcement will be made in due
course, providing details on the leather tanning capabilities, alongside an
update on other ongoing previously announced partnerships and proposed future
commercial opportunities.

 

Amelie Pichard, Founder and Creative Director of the Company said: "I drew a
lot of inspiration from the farming world of yesteryear to give my company a
different approach to fashion. A direct sale, a company on a human scale, a
de-standardization, a sustainability of craftsmanship, a natural rhythm. For
me, using natural, laboratory-grown leather that doesn't harm animals or the
planet represents technology at the service of good Innovation. I'm delighted
to be able to create a real bridge between innovation and tradition with this
first lab-grown-leather goods item."

 

Che Connon, Managing Director of BSF Enterprise and CEO of 3DBT,
commented: "We are delighted to be collaborating with a company that has led
the way in environmentally friendly fashion. Utilising lab-grown leather is an
inevitable next step for the fashion industry if it is to create a sustainable
future and it is extremely exciting to be working toward being the first at
doing this. We look forward to providing further updates on the progress of
this partnership in due course."

 

For further enquiries, please visit www.bsfenterprise.com
(http://www.bsfenterprise.com/)  or contact:

 BSF Enterprise PLC                       Via SEC Newgate below
 Geoff Baker - Executive Director

 Che Connon - CEO & Director

 Shard Capital (Broker)
 Damon Heath                              0207 186 9000

 Isabella Pierre                          0207 186 9927

 SEC Newgate (Financial Communications)
 Bob Huxford                              020 3757 6882

 Elisabeth Cowell                         BSF@secnewgate.co.uk

 

 

 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

 

Notes to Editors

 

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of
biotechnological solutions - using cell-based tissue engineering to help
generate cultured meat, lab-grown leather, as well as human corneas, collagen
growth and skin substitutes, as part of a radical transformation to deliver
sustainable solutions across a variety of sectors.

 

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with
patent-protected IP that is already producing human corneas for testing to
help restore vision to millions of people. Building on this success, it aims
to produce the UK's first high quality lab-grown meat and leather from its
laboratory in Newcastle, transforming the meat-production industry and the
leather industry towards an ethical and sustainable practice.

 

BSF aims to deliver growth to shareholders through the continued
commercialisation of 3DBT's IP, which has multiple applications, as well as
through M&A. It aims to develop a suite of technologies that underpins the
development of tissue templating for corneas, meat and leather, and license
out the IP to manufacturers, wholesalers and distributors to help manufacture
the products at scale.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCLVLLLZLLBBBL